The concentration of new and doubled positions from high-conviction active funds (Point72, Citadel, Two Sigma) signals strong institutional belief in near-term catalysts. Monitor for atacicept Phase 3 data or regulatory updates. The Morgan Stanley exit is a cautionary signal but appears idiosyncratic given the broad buying.
VERA drugs
VERA drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 11 $33.65entry
- T+1 · 5mo ago +1.81%α +1.27% · $34.26
- T+5 · 5mo ago +4.04%α +3.61% · $35.01
- T+20 · 4mo ago +26.15%α +24.26% · $42.45
- T+60 · 2mo ago +6.66%α +2.26% · $35.89
How similar events traded
Executive Summary
Seven institutional investors accumulated $115.7M in VERA during Q3 2025, led by Point72's new $37M position and Citadel's doubling to $46.9M, while Morgan Stanley nearly exited its $52.7M stake. The cluster is dominated by active quant and asset-manager buyers, suggesting a shared thesis around Vera's pipeline catalysts (likely atacicept in IgA nephropathy) outweighing the risk-off signal from Morgan Stanley's exit.
Key Financial Metrics
Institutional Positions
Net institutional flow: $44.0M
▲ Buyers (7)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Point72 | NEW | Not reported | $37.0M | $37.0M |
| Citadel | DOUBLED | +187% | $46.9M | $33.7M |
| Dimensional Fund Advisors | DOUBLED | +134.5% | $10.5M | $6.9M |
| Nuveen | DOUBLED | +191.5% | $9.2M | $6.7M |
| Two Sigma | ADD | +32.9% | $5.0M | $1.9M |
| UBS | ADD | +57.5% | $4.7M | $2.3M |
| Wells Fargo | DOUBLED | +140% | $2.4M | $1.6M |
▼ Sellers (2)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Morgan Stanley | NEAR_EXIT | -87.7% | $52.7M | -$44.8M |
| Ubs Am, A Distinct Business Un | TRIM | -46.3% | $3.6M | -$1.2M |
Key Facts
- 7 buyers accumulated $90.0M net; 2 sellers reduced by $46.0M
- Point72 initiated a new $37.0M position (1.27M shares)
- Citadel doubled its stake to $46.9M (+$33.7M)
- Morgan Stanley cut 87.7% of its position, exiting $44.8M
- Active managers (Point72, Citadel, Two Sigma) drove 80% of buying value
- Passive rebalancing by Wells Fargo and UBS added modest $3.9M combined
Financial Impact
Net institutional buying of $44.0M (7 buyers added $90.0M, 2 sellers removed $46.0M) represents ~1.9% of VERA's $2.3B market cap
Risk Factors
- 13F data is 45+ days stale; positions may have been unwound
- Morgan Stanley's near-exit could reflect material non-public concerns
- Biotech binary catalyst risk, any pipeline setback would reverse the thesis
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-VERA-2025-Q3 |
Track record
25 reports on VERA
12 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +36.47% at T+20 after the Jun 2, 2026 report. 13 of 13 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $27.55 settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $30.03 settles Nov 17
- Nov 5, 202611d ago 8-K Bullish 6/10 No price data
- Nov 5, 202611d ago Press Release Bullish 6/10 Entry $29.79 to $28.10 ▼ −5.66% −8.25% vs SPY
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $31.97 to $30.48 ▼ −4.66% −3.75% vs SPY
- Oct 22, 202625d ago Press Release Bullish 8/10 Entry $29.05 to $30.53 ▲ +5.09% +4.39% vs SPY
- Sep 15, 20268w ago 8-K Bullish 8/10 Entry $33.67 to $34.00 ▲ +0.98% +0.16% vs SPY
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers